<DOC>
	<DOCNO>NCT00786006</DOCNO>
	<brief_summary>The investigator evaluate efficacy safety FOLFOX FOLFIRI.3 combination chemotherapy second-line salvage chemotherapy patient advance pancreatic carcinoma .</brief_summary>
	<brief_title>Randomized Phase II Study FOLFOX Versus FOLFIRI.3 Gemcitabine-refractory Pancreatic Cancer</brief_title>
	<detailed_description>Given poor response rate , usually less 20 % gemcitabine-based doublet first-line setting advance pancreatic cancer , additional problem therapeutic management common malignant disease constitutes need effective treatment alternative patient fail gemcitabine-based chemotherapy . To date , study assess second-line chemotherapy primarily due poor prognosis , limited life expectancy advance pancreatic cancer failure first-line chemotherapy , establish second-line treatment pancreatic cancer failure gemcitabine . 1 . Oxaliplatin combination 5-FU ( FOLFOX ) Oxaliplatin , diaminocyclohexane-platinum , alkylating agent inhibit DNA replication form adduct two adjacent guanine guanine adenine molecule . With regard inhibition DNA synthesis , adduct oxaliplatin appear effective cisplatin adduct . Synergism oxaliplatin 5-FU demonstrated vitro , vivo . Combination oxaliplatin 5-FU proven effective first- second-line treatment advance colorectal cancer . After extensively developed treatment colorectal cancer , role oxaliplatin upper gastrointestinal malignancy include pancreatic cancer emerge area investigation . In preclinical study , oxaliplatin cytotoxic activity pancreatic cancer cell line . When use single agent first-line treatment second-line treatment failure gemcitabine-based chemotherapy , oxaliplatin minimal activity pancreatic cancer . However , use 5-FU , produce 10 % objective response rate 21 % clinical benefit response minimal toxicity chemotherapy-naïve patient . In phase II study second-line treatment , oxaliplatin 5-FU well tolerate produce objective response rate 23.3 % additional 30.0 % patient achieve stable disease . Furthermore , recently Oettle et al . report weekly infusional 5FU/LV oxaliplatin prolongs survival improve quality life advance pancreatic cancer gemcitabine failure compare best supportive care alone . 2 . Irinotecan combination 5-FU ( FOLFIRI.3 ) Irinotecan strong growth-inhibiting effect culture pancreatic adenocarcinoma cell . It also highly active pancreatic tumor cell culture xenograft model . Irinotecan monotherapy test patient previously untreated pancreatic cancer , yield response rate 9-27 % . In vitro study indicate synergism irinotecan 5-FU sequence dependent , cytotoxicity strong irinotecan administer 5-FU . Recently , French study group report FOLFIRI.3 regimen , comprise irinotecan D1 D3 5-FU 2 day D2 , promise activity chemotherapy-naïve pretreated patient advanced pancreatic cancer . The confirmed response rate 37.5 % median progression-free survival 5.6 month . The study also suggest cross-resistance gemcitabine FOLFIRI.3 . The investigator evaluate efficacy safety FOLFOX FOLFIRI.3 combination chemotherapy second-line salvage chemotherapy patient advance pancreatic carcinoma .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>1 . Pathologically proven pancreatic adenocarcinoma 2 . Age 18 year old 3 . ECOG performance status 2 low 4 . Documented disease progression receive within 6 month discontinue gemcitabinebased firstline adjuvant chemotherapy 5 . Adequate bone marrow function A. WBCs &gt; 4,000/µL , absolute neutrophil count [ ANC ] &gt; 1,500/µL B. Hemoglobin &gt; 9.0 g/dL C. Platelets &gt; 100,000/µL 6 . Adequate kidney function ( creatinine &lt; 1.5 mg/dL ) 7 . Adequate liver function ( bilirubin &lt; 1.5 mg/dL [ &lt; 2.5 mg/dL obstructive jaundice adequately decompress bile duct obstruction ] , transaminases level &lt; 3 time upper normal limit , serum albumin &gt; 2.5 mg/dL ) 8 . No serious medical condition would preclude treatment 1 . Other tumor type adenocarcinoma 2 . Evidence GI bleeding GI obstruction 3 . Presence history CNS metastasis 4 . Axial skeletal radiotherapy within 6 month 5 . Neuropathy grade 2 worse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>irinotecan</keyword>
	<keyword>fluorouracil</keyword>
	<keyword>Failure gemcitabine chemotherapy</keyword>
</DOC>